Navigation Links
Non-Polyp Colon Lesions Hard to Detect
Date:3/4/2008

id. "This study emphasizes the need for a high-quality examination with a fully-trained endoscopic technician," he added.

More information

To learn more about colonoscopy, visit the American Gastroenterological Association.



SOURCES: Roy M. Soetikno, M.D., M.S., chief of gastroenterology, Veterans Affairs Palo Alto Health Care System, California; David Lieberman, M.D., professor of medicine, and chief, division of gastroneterology, Oregon Health and Science University, Portland; March 5, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. SGV Medical Supplies: Colostomy Supplies Easier to Obtain for the Colon Cancer Survivor
2. Mouse study: Real-time imaging device may improve surgery for congenital colon disease
3. Earlier Colon Cancer Screens Urged for Smokers
4. What are simple ways to judge the efficacy of 5-fluorouracil in colonic neoplasm?
5. A rare diagnosis in the operation room: Kidney atrophy due to duplicated colon in an adult
6. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
7. US cancer deaths down but far too few Americans screened for colon cancer
8. U.S. Cancer Deaths Down But Far Too Few Americans Screened for Colon Cancer
9. The Facts African Americans Need to Know About Colon Cancer
10. Smokers might benefit from earlier colon cancer screening
11. Colonial Life Goes One On One With ESPN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)... SAN FRANCISCO, Jan. 8 M... that David Hung, M.D., president and chief,execu... Morgan Healthcare,Conference on Wednesday, Janua...t. Francis Hotel in San Francisco. , Dr. Hu...clinical,development programs for Dimebon for Alz...
(Date:1/8/2009)...HINGTON, Jan. 8 The Pew...son has been named director, chemical and food saf...olicy program. Olson, who was formerly deputy staf...ttee on Environment and Public Works, brings nearl...nd consumer advocacy to Pew. , , "We are excit...
(Date:1/8/2009)...ould be used when assessing traditional risk facto...althDay News) -- Two molecular signs -- or "biomar...ation when trying to assess a person,s risk of str... or very low risk, adding these markers does not c...ay Nambi, a cardiologist at the Methodist DeBakey ...
(Date:1/8/2009)...hy Tune Promoted to Principal. Christine Siu and ..., MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn.,...tners, a health care venture capital firm that inv...ies, today announced the promotion of three member...moted to Principal. Christine Siu and Jason Brown...
Breaking Medicine News(10 mins):Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2Health News:Inflammation Markers May Help Predict Stroke Risk 2Health News:Inflammation Markers May Help Predict Stroke Risk 3Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2
... to findings of a recent study , 70 percent of all... ill individuals.// Researchers studied nearly 43,...p homes to explore the correlation between patient...nd drug use. Results showed 28 percent of patients...
...rs now say they’ve found one drug that may success...cer.// In a study of 22 patients with breast, pros...42 percent had their tumors either stabilize or sh...y , it turns off one of the switches within the ca...
...of a new study shows that high-doses of vitamin E...erall risk of early death.// Vitamin E is one of ...wth and function. On average, dietary intake of vi...y. Other sources of the vitamin include wheat germ...
...rs say there may be a new way to correct hard-to-t...g during a minimally // invasive surgical procedur...ure a more complete correction. Birthmarks basica...le with the birthmarks do not experience problems,...
Other Medicine News:
(Date:1/6/2009)...swire-FirstCall/ -- , - Early Renewal of th...ember 2011 , - Expansion of the Scope of th...Ophthalmology , - Revised Commercial Terms ...o a Third Party , ExonHit Therapeutics (A...of its existing drug discovery collaboration with ...
(Date:12/30/2008)...ewswire/ -- The Coalition for 21st Century Medicin...enentech, Inc. on December 5, 2008, seeking to res...tic tests to physicians and patients. The request...arm patient care and rests on flawed scientific an...s to encourage the research, development, and comm...
(Date:12/17/2008)...t and validation of non-animal alternative test me...re/ -- MatTek Corporation today announced that the...ed the scientific validity of the Modified EpiDerm...g. ESAC concluded that the Modified EpiDerm SIT h...diction of skin irritating and non-irritating test...
(Date:12/17/2008)...l/ -- Delcath Systems, Inc. (Nasdaq: DCTH ) toda...h.D., to Delcath,s Board of Directors. Dr. Contag...perience working with international and domestic i....com/cgi-bin/prnh/20081118/NY46990LOGO ) , ,... 2006 and served as CEO. Prior to starting Cobalt...
Breaking Medicine Technology:ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Dragon retains leading investor relations firm 3999 1Dragon retains leading investor relations firm 3999 2Dragon retains leading investor relations firm 3999 3QuoNova Global Executive Appointments 3994 1QuoNova Global Executive Appointments 3994 2QuoNova Global Executive Appointments 3994 3QuoNova Global Executive Appointments 3994 4Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 1Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 2Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 3Fludarabine Mitoxantrone and Zevalin 28R 29 Produces 96 25 Complete Remission Rate in First Line Treatment of Patients with Follicular Non Hodgkins L 1531 4New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 1New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 2New Brain Fitness Training Promotes Health and Independence of Long Term Care Insurance Policyholders 14470 3
...ries, Inc. Today,Announced the Top Line Results of...) Study with the Compound Desmoteplase , Aachen (G...k,Exchange, Prime Standard: PA8) and its US partne...unced topline results of,the DIAS-2 (Desmoteplase ...Desmoteplase. The Phase III study was designed to,...
...tCall/ - Research,collaborators with Oncolytics Bi... a poster presentation covering REOLYSIN(R),clinic...Oncology,(ASCO) Annual Meeting, to be held June 1-...f Oncolytics, U.K. Phase I systemic,administration... Phase I Study of,Wild-Type Oncolytic Reovirus Adm...
Other Medicine Technology:Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Top Line Results of Phase III Study in Acute Ischemic Stroke,(DIAS-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: